BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 114.13 USD 0.55% Market Closed
Market Cap: 27.5B USD
Have any thoughts about
BioNTech SE?
Write Note

BioNTech SE
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioNTech SE
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
BioNTech SE
NASDAQ:BNTX
Free Cash Flow
€4.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Free Cash Flow
-€300.7m
CAGR 3-Years
-6%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Free Cash Flow
-€323.1m
CAGR 3-Years
N/A
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Free Cash Flow
-€12.7m
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Free Cash Flow
-€36.1m
CAGR 3-Years
N/A
CAGR 5-Years
-13%
CAGR 10-Years
9%
Formycon AG
XETRA:FYB
Free Cash Flow
-€31m
CAGR 3-Years
-86%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BioNTech SE
Glance View

Market Cap
27.4B USD
Industry
Biotechnology

BioNTech SE, founded in 2008 by the visionary duo Ugur Sahin and Özlem Türeci, has gradually emerged as a shining beacon in the world of biotechnology. Situated in Mainz, Germany, BioNTech carved its niche by focusing on the development of personalized therapies for cancer and other serious diseases. The company’s core competence lies in utilizing messenger RNA (mRNA) technology, which allows it to instruct the body to produce proteins that can stimulate an immune response. This technology became a game changer, not only in the cancer arena but also expanded its reach into infectious diseases, showcasing a broader horizon of possibilities. BioNTech’s ability to leverage its research expertise in mRNA placed it at the forefront of scientific innovation, demonstrating breathtaking adaptability and ingenuity. The company's business model thrives on strategic partnerships and collaborations, which bolster both its scientific output and financial standing. One of its most celebrated partnerships is with Pfizer, a collaboration that led to the development of the groundbreaking COVID-19 vaccine, Comirnaty. This collaboration thrust BioNTech onto the global stage, underscoring its capacity to swiftly respond to urgent health crises while generating substantial revenue. The success and distribution of the vaccine not only provided a significant boost to BioNTech’s financials but also validated its platform as powerful and versatile. By continually investing in research and development, both independently and through alliances, BioNTech aims to solidify its position as a leader in the evolving biotech landscape, paving the way for future therapies that could redefine medical treatments.

BNTX Intrinsic Value
32.68 USD
Overvaluation 71%
Intrinsic Value
Price

See Also

What is BioNTech SE's Free Cash Flow?
Free Cash Flow
4.7B EUR

Based on the financial report for Dec 31, 2023, BioNTech SE's Free Cash Flow amounts to 4.7B EUR.

What is BioNTech SE's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
-65%

Over the last year, the Free Cash Flow growth was -65%.

Back to Top